AbbVie ABBV continued its acquisition spree with the announcement of a definitive agreement to acquire private biotech Nimble ...

But making AbbVie an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of ABBV ...

As AbbVie Ireland’s new general manager, Dana Kendall will oversee the company’s commercial business in the country.

AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.

The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...

Kendall has over 18 years of extensive pharmaceutical industry experience across sales, marketing, and leadership roles in ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial ...

The acquisition includes Nimble's investigational candidate, an oral peptide IL23R inhibitor to treat psoriasis.

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

These companies have ingrained competitive advantages in an evergreen industry backed by decades of dividend growth.

Shares of AbbVie Inc. ABBV inched 0.10% higher to $173.37 Friday, on what proved to be an all-around mixed trading session ...

Buying Nimble Therapeutics represents AbbVie's latest deal to build out a pipeline in the wake of fading sales of its once ...